Rigel Pharmaceuticals (RIGL) Change in Accured Expenses (2010 - 2026)

Rigel Pharmaceuticals' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 39.34% year-over-year to -$1.8 million in Q1 2026; TTM through Mar 2026 was $2.9 million, a 51.47% increase from a year earlier, with the FY2025 full-year figure at $1.8 million, up 21.33% from the prior year.
• Change in Accured Expenses eased to -$1.8 million in Q1 2026 per RIGL's latest filing, from $1.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.9 million in Q2 2022 and bottomed at -$4.1 million in Q1 2022.
• The 5-year median for Change in Accured Expenses is $672000.0 (2023), against an average of $55705.9.
• Biggest YoY gain for Change in Accured Expenses was 500.3% in 2024; the steepest drop was 312.08% in 2024.
• Year by year, Change in Accured Expenses stood at $3.6 million in 2022, then tumbled by 120.77% to -$753000.0 in 2023, then tumbled by 312.08% to -$3.1 million in 2024, then jumped by 159.59% to $1.8 million in 2025, then tumbled by 196.92% to -$1.8 million in 2026.
• Per Business Quant, the three latest RIGL Change in Accured Expenses figures stand at -$1.8 million (Q1 2026), $1.8 million (Q4 2025), and $2.2 million (Q3 2025).